Helper-free Production of Laboratory Grade AAV and Purification by Iodixanol Density Gradient Centrifugation
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) is one of the most promising gene therapy vectors and is widely used as a gene delivery vehicle for basic research. As AAV continues to become the vector of choice, it is increasingly important for new researchers to have access to a simplified production and purification protocol for laboratory grade recombinant AAV. Here we report a detailed protocol for serotype independent production of AAV using a helper-free HEK293 cell system followed by iodixanol gradient purification, a method described earlier. 1 While the core principals of this mammalian AAV production system are unchanged, there have been significant advancements in the production and purification procedure that serve to boost yield, maximize efficiency, and increase the purity of AAV preps. Using this protocol, we are able to constantly obtain high quantities of laboratory grade AAV particles (>5 × 10 12 vg) in a week's time, largely independent of serotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 2×
“HEK293 cells are specifically required for the helper-free method as they stably express the Ad E1A/E1B genes which, in combination with pHelper, provide full Ad helper function.(13) This is the most flexible method for producing rAAV as any changes in serotype or transgene can be made by editing the plasmid construct…”
BackgroundMethodKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Piedra, J., Ontiveros, M., Miravet, S., Penalva, C., Monfar, M., & Chillon, M. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2014.120 · Cited by 70
Research works printed but not linked: 11
- Zolotukhin, 1999, Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Ther., 6, 973, 10.1038/sj.gt.3300938 · DOI · Paper page
- Podsakoff, 1994, Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors, J. Virol., 68, 5656, 10.1128/jvi.68.9.5656-5666.1994 · DOI · Paper page
- Flotte, 1998, A fluorescence video-endoscopy technique for detection of gene transfer and expression, Gene Ther., 5, 166, 10.1038/sj.gt.3300579 · DOI
- Senís, 2014, CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox, Biotechnol. J., 9, 1402, 10.1002/biot.201400046 · DOI · Paper page
- Booth, 2004, Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids, Gene Ther., 11, 829, 10.1038/sj.gt.3302226 · DOI
- Urabe, 2002, Insect cells as a factory to produce adeno-associated virus type 2 vectors, Hum. Gene Ther., 13, 1935, 10.1089/10430340260355347 · DOI · Paper page
- Mietzsch, 2014, OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy, Hum. Gene Ther., 25, 212, 10.1089/hum.2013.184 · DOI · Paper page
- Zolotukhin, 2002, Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors, Methods, 28, 158, 10.1016/S1046-2023(02)00220-7 · DOI · Paper page
- Zolotukhin, 1996, A “humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells, J. Virol., 70, 4646, 10.1128/jvi.70.7.4646-4654.1996 · DOI · Paper page
- Hildinger, 2001, Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer, J. Virol., 75, 6199, 10.1128/JVI.75.13.6199-6203.2001 · DOI · Paper page
- Grieger, 2016, Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector, Mol. Ther., 24, 287, 10.1038/mt.2015.187 · DOI · Paper page
Cited by
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning
Nonnenmacher, M., Wang, W., Child, M. A., Ren, X.-Q., Huang, C., Ren, A. Z., Tocci, J., Chen, Q., Bittner, K., Tyson, K., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.006 · Cited by 168
“Lysate and supernatant fractions were pooled and fractionated on two successive rounds of iodixanol gradients as previously described.(47) Buffer exchange was performed on Amicon-100 columns (Millipore) with phosphatebuffered saline containing 200 mM total NaCl and 0.”
MethodWang, C., Mulagapati, S. H. R., Chen, Z., Du, J., Zhao, X., Xi, G., Chen, L., Linke, T., Gao, C., Schmelzer, A. E., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.006 · Cited by 105
Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80
“All AAV vectors were purified by double iodixanol gradient centrifugation and titers determined by quantitative PCR (29).”
MethodShirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
“Vector particles were purified by iodixanol gradient centrifugation, and titers were determined by dot blot hybridization and confirmed by western blot using a reference standard of known titer for comparison.(68)”
Method
Metadata
- Authors
- Crosson, S. M., Dib, P., Smith, J. K., & Zolotukhin, S.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 10
- Pages
- 1-7
- ISSN
- 2329-0501 (ISSN-L)
- OpenAlex
- W2800711204
- Cited by
- 79
- References
- 7
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- National Institute on Deafness and Other Communication Disorders (F31DC015751, R01DC012819)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Helper-free Production of Laboratory Grade AAV and Purification by Iodixanol Density Gradient Centrifugation. https://app.cochat.ai/papers/10.1016/j.omtm.2018.05.001
- The paper
- Crosson, S. M., Dib, P., Smith, J. K., & Zolotukhin, S. (2018). Helper-free Production of Laboratory Grade AAV and Purification by Iodixanol Density Gradient Centrifugation. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2018.05.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.